PT ENSEVAL PUTERA MEGATRADING Tbk … ENSEVAL PUTERA MEGATRADING Tbk COMPANY UPDATE YTD 30 SEPTEMBER...
Transcript of PT ENSEVAL PUTERA MEGATRADING Tbk … ENSEVAL PUTERA MEGATRADING Tbk COMPANY UPDATE YTD 30 SEPTEMBER...
PT ENSEVAL PUTERA MEGATRADING TbkCOMPANY UPDATE
YTD 30 SEPTEMBER 2010 RESULTS
Table of Contents
• Enseval In BriefSection
I
• Business Overview Section
II
• Operational HighlightsSection
III
• Financial HighlightsSection
IV
I. Enseval In Brief
-
1,000
2,000
3,000
4,000
5,000
6,000
7,000
8,000
9,000
Net Sales
(100)
(50)
-
50
100
150
200
250
300
350
Laba (Rugi) Bersih
Sustainable Growth during last 15 years
1973:PT Ensevalestablished in Oct 1973
1973 1993
1993 :Trading & distribution activities transferred to subsidiary, Arya Gupta Cempaka, later known as PT EPM
1994
1994: The Company was listed on Indonesian Stock Exchange
2003
2003: Incorporation of Subsidiary PT Milenia Dharma Insani
2007
2007: Incorporation of Subsidiaries PT EnsevalMedika Prima & PT Global Chemindo Megatrading
2008
2008: Incorporation of Subsidiaries PT RenalmedTiara Utama
Milestones
• Largest Pharmaceutical distribution company in Indonesia with 42 full-service branches, 2 Regional Distribution Company and 23 branches under subsidiary & employs more than 5.000 employees
Market Leading Position in Indonesia
• Distributes more than 10 well known OTC products, nutrition products, infant milk, energy drinks and Ethical Products
Strong Product Portfolio & Diversification
• Public listed company with professional management that ensure fairness treatment to all Principals & all stakeholders
Good Corporate Governance
• Strong Net Sales growth with CAGR 12.6% from year 2005-2009 • Robust balance sheet figures
Strong Financial Track Record
• Committed for continuous improvement (ISO 9001:2008, GDP & OHSAS)
• Commitment to always increase market coverage and to invest and own directly all its assets, land, building, IT infrastructure, and transportation armada to serve better
Enseval’s Commitment Towards Improvement
Enseval In Brief
Shareholding Structure
PT Enseval PuteraMegatrading
Tbk
PT Tri Sapta Jaya
99.9%
PT MileniaDharma Insani
100.0%
PT EnsevalMedika Prima
100.0%
PT Global ChemindoMegatrading
100.0%
PT Renalmed Tiara Utama
97.5%
Kalbe 83.75%
Publik16.25%
II. Business Overview
Distribution & LogisticProduct Range : Ethical, OTC, Consumer Products, Medical Device &
Raw Material
Our service :
Warehousing
Inventory Management
Freight & Transportation
Sales & Support
Order-taking, Billing & Collection
Distribution & Logistic
Covers more than 150.000 outlets throughout Indonesia
Cover most pharmacies & hospital
Cover 80% of consumer & health market
24 hour order fulfillment & 4-5 hour order fulfillment for prescription
medicines
24 hour service for life saving drug
Offers value added services to customers
Medical DeviceProduct Range : Consumables, Instruments, Laboratories & Diagnostics, and
Products related to Laboratories Industry
The Company offers Marketing services for medical devices through its subsidiary, PT Enseval Medika Prima and Hemodialysis Treatment in collaboration with clinics and hospitals through PT Renalmed Tiara Utama.
The company has retained the trust & maintained good relationships with multi-national principals
Raw Material
Related to : Pharmaceutical Product, Food, Cosmetics & Veterinary
PT Global Chemindo Megatrading offers trading & marketing ofraw material and has extensive network and collaboration withMultinational Companies from different countries, such as : UnitedStates, Europe, China, Japan, Korea and other countries.
Healthcare Services Healthcare Services through Mitrasana Clinics ,with facilities such as:
Clinic, Pharmacy, Laboratory & Mini market, which now also offers Hemodialysis treatment.
Until 30 Sept 2010, The Company has 20 Clinics in Jakarta and its greater areas
Offered in 2 business models : direct investment & collaboration / joint operation models
III. Operational Highlights
Branches The largest pharmaceutical distribution network throughout theIndonesian Archipelago with 42 Branches (EPM), 2 Regional DistributionCenter, Located in Jakarta & Surabaya & 23 Branches under subsidiarycompany (TSJ)
Events Highlights in 2010
The Company awarded as ‘Pharmaceutical distribution Company that has the most outlet’ from Rekor Bisnis Indonesia in February
The Company conducted its AGMS on May 18, 2010
In June 2010, PT Perkebunan Nusantara VIII joined as new principal with its ready to drink tea product ‘ Walini Tea’
Operationals Highlights in 2010
Infrastructures & Branches Development in branches, such as : Aceh, PematangSiantar, Solo, Jember & Banjarmasin
The Company has completed audit for OHSAS (Occupational Health & Safety Certification for its Logistic Department
Some initiatives for service quality improvement: - Enseval Customer Care (ECC) Implementation - Subdistributor Appointment to expand distribution coverage throughout Indonesia- 24 hours Call Center Implementation, ‘After Sales Service’ & ‘Customer Service Online’ in PT Enseval Medika Prima, The Company’s Subsidiary
From IT point of view, The Company has completed Oracle ERP version upgrade & Oracle Demantra Implementation (Sales Forecasting System)
The Company Subsidiary, PT Enseval Medika Prima & PT Global Chemindo Megatradinghave been known in Medical Devices & raw material market in Indonesia & gained trust from Multinational Principals
The Company open 14 Mitrasana Clinics in Jakarta & its greater area in 2010, Until 30 Sept 2010, the Company has 20 Clinics
Corporate Social Responsibility‘Enseval Berbakti’ program :
Blood Donation, every 3 months in 42 branches
Plantation of more than 800 trees in the company’s 42 branches
Scholarship program for employees children
Human Resources Employs over 5,000 personnel with over 2,000 personnel are working in sales and
distribution
The Company continues to provide training for all employees to improved its human resources competencies
In year 2010, The Company continues to promote CONIM Program (ContinuosImprovement) to all staffs, both in Headquarters & in all Branches.
Principals Based on Categories
OTC Consumers Product Ethical
Major Principals
Principals Based on Categories
Medical Devices & Diagnostic Raw Material
Friesland Foods Domo
Major Principals
Infrastructures
More than 580 Transportation FleetMore than 120 Motorcycles
More than 61.000 Pallets Size
The Usage of Oracle System as IT Platform
IV. Financial Highlights
Financial Highlights
Net Sales Operating Income
Until YTD 30 Sept 2010, The Company recorded Net Sales of IDR 6.9 trillion, 12.1% growth YoY, with Operating Income amounting to IDR 206.5 billion
307
363
484
207
4.8%4.9%
5.7%
3.0%
0%
1%
2%
3%
4%
5%
6%
0
100
200
300
400
500
600
2007 2008 2009 YTD 09 2010
Laba Usaha Marjin Laba Usaha
6,4
7,4
8,6
6,9
15.4% 16.1%15.7%
12.1%
0%
2%
4%
6%
8%
10%
12%
14%
16%
18%
0
1
2
3
4
5
6
7
8
9
10
2007 2008 2009 YTD 09 2010
Penjualan Bersih (Miliar Rp) Pertumbuhan (%)
Financial Highlights
231
267
329
143
3.6%
3.6%3.9%
2.1%
0.0%
0.5%
1.0%
1.5%
2.0%
2.5%
3.0%
3.5%
4.0%
4.5%
0
50
100
150
200
250
300
350
2007 2008 2009 YTD 09 2010
Net Income (IDR Million) Net Profit Margin
Net Income
102
117
144
63
0
20
40
60
80
100
120
140
160
2007 2008 2009 YTD 09 2010
Net Income Per Share (IDR)
Net Income Per Share
Until YTD 30 Sept 2010, The Company Net Income reached IDR 143.1 million with Net Income Per Share of IDR 63
2,228
1,778
1,256
482 359
23
2,639
2,107
1,231
537
331
22
Consumer Products Ethical OTC Raw Material Medical Device Others
YTD 09 2009 YTD 09 2010
11.4%
5.2%
2.0%
18.5%
18.4%
7.8%
Net Sales By Division
Sales ContributionPada Periode 30 Sept 2010 ,Kalbe Group’s Net Sales Contributes 72% from total net sales , while the remaining 28% from 3rd party prinsipal .
72%
28%
72%
28%
Kalbe Grup
3rd Party
YTD 30 Sept 2010 YTD 30 Sept 2009
Sales Contribution
Consumer Products
38%
Ethical 31%
OTC 18%
Medical Device
8%
Raw Material 5%
Others0%
YTD 092010 233
315
502
673
FY 2006 FY 2007 FY 2008 FY 2009
310
414
581
714
FY 2006 FY 2007 FY 2008 FY 2009
4,979 5,639
6,310
7,163
FY 2006 FY 2007 FY 2008 FY 2009
CAGR 12,9%
Medical Device
Net Sales (in IDR Billion )
Raw Material
CAGR 42,3%
CAGR 32,1%
2,625
391
3,016 2,980
491
3,471
Current Assets Non Current Assets Total Assets
30 Sept 09 (IDR Billion) 30 Sept 10 (IDR Billion)
13.5%
25.8%
15.1%
Assets
1,482
45
1,527 1,701
86
1,787
Current Liablities Non Current Liabilities Total Liabilities
30 Sept 09 (IDR Billion) 30 Sept 10(IDR Billion)
Liabilities & Equity
1,489
1,684
Equity
30 Sept 09 (IDR Billion) 30 Sept 10 (IDR Billion)
17.0%
13.1%
91.0%
14.8%
Thank You For further information, please contact :
PT Enseval Putera Megatrading Tbk.
Enseval Building, Kawasan Industri Pulogadung
Jalan Pulolentut No.10
Jakarta 13920 – Indonesia
Phone : 62-21-46822422 Fax : 62-21-4609039
Website : www.enseval.com
Email : [email protected]
IMPORTANT NOTICE
This presentation has been prepared for informational purposes only by PT Enseval Putera
Megatrading Tbk. (“Enseval” or the “Company”).
The information contained in this Presentation does not purport to be all-inclusive or to
contain all of the information that may be material to an investor’s decision. It should be
noted that the information contained in this Presentation is subjected to further review, and
that such information may be updated and/or amended from time to time as
circumstances change or more information becomes available. Some of those revisions or
changes may be material.
Each recipient of this Presentation should therefore perform their own independent
analysis of the business, operations, financial condition, creditworthiness, status and
affairs of Enseval. Each recipient should also conduct their own enquiries into the
adequacy, accuracy, and completeness of any information relating to Enseval, as the
information and data contained in this Presentation are not substitutes for the recipient’s
independent evaluation and analysis.
This presentation is not an offering document and will be updated regularly as necessary.